Israeli authorities said on Sunday that minors aged 5 to 11 will now be eligible for the weaker dosing of the Pfizer COVID-19 vaccine after a majority of experts on its advisory committee voted in favor of the vaccine’s safety profile. The decision, announced by Israel’s Health Ministry, cited Pfizer’s clinical trial data, which the company says indicates a 90.7 percent efficacy in preventing illness in the age group. The decision comes on the heels of an emergency approval for the pediatric vaccine in the United States. The U.S. Centers for Disease Control and Prevention (CDC) last week recommended the Pfizer-BioNTech pediatric shot for broad use in children aged 5-11, after the Food and Drug Administration (FDA) granted emergency use authorization. When Pfizer’s data was reviewed by the FDA’s Vaccines and Related Biological Products Advisory Committee, 17 of 18 panelists voted to recommend it for the age group. One panelist, National …